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In Alzheimer’s disease (AD), besides the characteristic deterioration of memory, studies
also point to a higher pain tolerance in spite of sensibility preservation. A change in the
normal tau protein phosphorylation is also characteristic of AD, which contributes to the
pathogenesis of the disease and is useful in early diagnosis. Kyotorphin (KTP) is an endoge-
nous analgesic dipeptide (Tyr-Arg) for which there is evidence of eventual neuroprotective
and neuromodulatory properties. The objective of this work was to study the possible cor-
relation between KTP and phosphorylated tau protein (p-tau) levels in cerebro-spinal fluid
(CSF) samples of AD patients. CSF samples were collected from 25 AD patients and 13
age-matched controls (N), where p-tau and KTP levels were measured. We found a statis-
tically significant difference between p-tau/KTP values in AD and N groups with an inverse
correlation between p-tau and KTP values in AD samples. These results suggest that in
the future KTP may be a candidate biomarker for neurodegeneration and may be a lead
compound to be used pharmacologically for neuroprotection.
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INTRODUCTION
Medical and pharmacological developments in recent years have
allowed a significant increase in aging of the population. Con-
comitant with the aging of the population the number of people
with dementia has increased. Alzheimer’s Disease (AD) is the
most prevalent neurodegenerative disease associated with demen-
tia. It is a progressive debilitating disease with no known effective
cure. Symptoms of memory loss begin at a variable age, usually
between 40 and 65 years of age, progressing with over the years. It
is expected that the current number of cases doubles by 2030, with
a huge social and economic impact (Knickman and Snell, 2002).
Patients suffering from AD show a progressive deterioration of
memory, orientation, emotional stability, speech, abstract think-
ing, motor skills, and ultimately self-care. The motor and cognitive
deterioration in AD patients is accompanied by a reduction in the
ability to communicate, which makes it difficult to detect pain
in these patients. By failing to receive adequate pain treatment,
structural and irreversible changes may occur in central systems
structures involved in the transmission/modulation of nociceptive
information, which accounts to chronic pain installation (Bor-
sook, 2012). Curiously, the two components of the pain response
are differentially affected in AD patients (Farrell et al., 1996;
Benedetti et al., 1999). Whereas the sensory-discriminative com-
ponent is preserved, pain tolerance, associated with the affective-
emotional aspect, largely increases. These apparent discrepancies
appear to have a neurobiological explanation since the somatosen-
sory cortex and thalamic nuclei involved in sensory-discriminating
component of pain response appear to be preserved in AD,
while the neuronal loss was detected in the prefrontal and limbic
structures, with obvious implications for and affective-emotional
pain-related reactions (Benedetti et al., 1999; Borsook, 2012).
In pathophysiological terms, AD is characterized by cognitive
losses, associated cholinergic deficit in the frontal brain area and
extensive neuronal loss as well as synaptic changes in the neuronal
pattern at the cortex and hippocampus. There is also evidence
of neuronal tangle formation, made up of tau protein. Tau pro-
teins are a group of neuronal microtubule-associated proteins,
having a role in the regulation of neurite outgrowth, microtubule
dynamics and axonal transport. There is strong evidence that in
AD there is a change in the normal tau phosphorylation, which
contributes to the pathogenesis of the disease. In fact, the abnormal
phosphorylation leads firstly to a loss of function with decreased
microtubule binding and, secondly, an increase of tau–tau interac-
tions with negative effects on the neuronal stability (Johnson and
Stoothoff, 2004). It has been well studied and commonly accepted
that abnormally phosphorylated tau (p-tau) is the major protein
subunit of Alzheimer’s paired helical filaments (PHFs), being use-
ful in the early diagnosis of this pathology (Kurz et al., 1998).
Tau is normally an intracellular protein, and the amount found
in cerebro-spinal fluid (CSF) is low. The slow neurodegenerative
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process that occurs in AD leads to increased neuronal loss which
may give rise to increased tau levels in CSF. CSF samples of AD
patients show high p-tau levels compared to normal subjects, cor-
relating with hyperphosphorylated tau in cortical brain biopsies
(Seppälä et al., 2012).
The other neuropathological hallmark of the AD is the forma-
tion of amyloid plaques, made of amyloid-β (Aβ) peptide, derived
from the amyloid precursor protein (APP). The “amyloid cascade
hypothesis” states that an imbalance between the production and
clearance of the Aβ is the initiating event in AD, with the increase in
Aβultimately leading to tau pathology,neuronal degeneration,and
dementia (Blennow et al., 2010). Aβ is produced during normal
cell metabolism and secreted into the CSF and can also be used as a
biomarker for AD, specifically its most abundant species – Aβ1–42,
with AD patients consistently exhibiting a decrease of Aβ1–42 in
CSF (Blennow, 2004; Blennow et al., 2010).
Kyotorphin (KTP) is a dipeptide (Tyr-Arg; Figure 1) with
endogenous analgesic properties, first described by Takagi et al.
(1979), isolated from bovine brain. It was subsequently isolated
from other sources, including the brains of mice and rats (Ueda
et al., 1980), guinea pig, rabbits, and squirrels (Ignat’ev et al.,
1998) and detected in the CSF in humans (Nishimura et al.,
1991). Despite being about fourfold more analgesic than endoge-
nous opioids (Shiomi et al., 1981a), KTP effect is only induced
after direct injection in the brain. This limited capacity to cross
the blood-brain barrier prevents its pharmacological applications.
KTP derivatives however have recently been demonstrated to
be analgesic after systemic administration in several pain mod-
els which indicates the ability of KTP derivatives to cross the
blood-brain barrier (Ribeiro et al., 2011a,b).
Kyotorphin is synthesized in nerve terminals and released by
depolarizing stimuli (Shiomi et al., 1981b). It may modulate
the synaptic transmission and directly excite cortical neurons.
It was proposed that it exerts indirect opioid-like actions, pro-
ducing analgesia through the release of met-enkephalin (Ribeiro
et al., 2011b). Other studies in animal models have revealed
the neuroprotective actions of KTP in the hippocampus and
cerebellum (Nazarenko et al., 1999; Bocheva and Dzambazova-
Maximova, 2004). In addition, there is further evidence that
the peptide has neuroprotective and neuromodulating properties
(Santalova et al., 2004; Dzambazova and Bocheva, 2010), also act-
ing as a neuroleptic and inhibiting calcium-dependent currents
in the post-synaptic membrane (Gorenkova et al., 2002; San-
talova et al., 2004). There is also an anticonvulsant effect reported
in animal models of epilepsy (Godlevsky et al., 1995; Shandra,
1999).
Although there is no immunohistochemical mapping
of kyotorphin-containing neurons in the brain, rat brain
homogenates show that the highest levels are found in the mid-
brain, pons, and medulla oblongata, correlating with the areas
most sensitive to morphine or electrical stimulation-induced anal-
gesia. However when the results are expressed as a percentage of the
total KTP found in different sections, the cortex seems to contain
around 50%, an area where enkephalins receptors are low, which
suggests that KTP non-opioid actions are important in its neu-
rochemical action (Ueda et al., 1982; Dzambazova and Bocheva,
2010). For KTP, a non-opioid activity was also described in the
FIGURE 1 | Kyotorphin chemical structure (L-tyrosyl-L-arginine).
peripheral nervous system and other organs like the heart (Inoue
et al., 1997; Li et al., 2006). It was shown that the KTP, due to its
l-Arginine residue, could act as substrate for nNOS [nitric oxide
synthase (NOS), located in neurons] (Arima et al., 1996, 1997).
Moreover, in recent years, there is increasing evidence that AD
may be primarily a vascular disease with neurodegenerative con-
sequences, rather than a neurodegenerative disorder with vascular
consequences (de la Torre and Stefano, 2000). Two key factors for
the development of AD have been proposed: aging and decreased
cerebral perfusion. The convergence of them will result in the
so-called “critically attained threshold of cerebral hypoperfusion”
(CATCH). It was proposed that the CATCH leads to a distortion
of the architecture of the brain capillary, involving impairment
of the release of nitric oxide (NO), which will affect the signaling
between the immune, nervous, and cardiovascular systems. Tis-
sues with decreased levels of NO may be severely deregulated. The
concomitance of advanced age and risk factors may contribute
to vascular lesions involving eNOS (located in the endothelium),
causing a deficit of NO to such a degree that this could initiate the
neurodegenerative changes characteristic of AD (de la Torre and
Stefano, 2000).
So it seems that KTP could function in two separate but
correlated domains: pain and neuromodulation. This assump-
tion would make us pose another question: when neuronal
death occurs, will there be a loss of KTP production that could
worsen neurodegeneration and with concomitant alteration of
pain threshold in patients? This would place KTP as a central
player in the amplification of the continuous degradation of the
clinical condition of AD patients. The goal of the present work was
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to study the possible correlation between KTP and p-tau levels in
CSF samples of Alzheimer patients to contribute to a better under-
standing of KTP mechanisms of action and open new horizons in
this area of research.
MATERIALS AND METHODS
All participants and caregivers were informed about the aim and
procedure of this work and gave their oral and written informed
consent prior to the commencement of the study.
We evaluated 25 patients with the diagnosis of AD, followed in
Neurology consultation at a Portuguese Hospital with moderate
cognitive impairment (stage 5 of the Global Deterioration Scale),
and 13 age and sex-matched controls. The control group com-
prised healthy patients, who underwent lumbar puncture because
of suspected (but not confirmed) subarachnoid hemorrhage or
other indications in the usual neurological survey. Subjects with
a history of cerebral trauma, transient ischemic attack, neoplasm,
epilepsy, disturbances of consciousness, or focal brain disorders
were excluded from participation in this study. Traumatic spinal
punctures (i.e., with evidence of blood contamination) were also
excluded from the study.
After lumbar puncture, the CSF samples were collected in poly-
ethylene tubes, protected from light exposure with aluminum foil
and stored at −80°C until analysis (without additional freeze-
thaw cycles). Appropriate evaluation of the degree of patient’s
dementia was performed by quantifying p-tau in CSF with a
commercial tau-specific sandwich ELISA kit (Innogenetics, Ghent,
Belgium).
Due to low levels of Kyotorphin that are estimated to be present
in the CSF (10−9 M) (Nishimura et al., 1991) it was necessary
to resort to advanced analytical techniques namely electrospray
ionization tandem mass spectrometry (ESI – MS/MS). The spec-
imens of CSF were dried under a stream of nitrogen, derivatized
with HCl-butanol and reconstituted with a solution contain-
ing CH3CN/H2O 7:3 and 15 mL/L formic acid. This procedure
it is similar to the routine method is used in our laboratory
for metabolite profiles in urine samples (Rebollido-Fernandez
et al., 2012). The solution was shaken on a vortex-mix system
for 15 min at room temperature, and 20µL solution was injected
into the mass spectrometer. Calibration solutions were prepared
with different additions of KTP in a CSF matrix, were at con-
centrations from 0.625 to 10 nM (Figure S1 in Supplementary
Material). We obtained a detection limit of 0.8 nM. The recovery
ranges between were 60.7 and 100.9%, at the working levels of
2.5 nM was 85.4%. The precision ranges between were 1.9 and
14.8%. We used an API 4000 triple quadrupole mass spectrometry
(Sciex Applied Biosystems) equipped with an electrospray source
with the turbo gas temperature set at 750°C. The equipment was
operated in positive ionization polarity at a potential of 5400 V.
We performed multiple reaction monitoring (MRM) measure-
ments, with Q1 394.3 and Q3 136.1 (Figure S2 in Supplementary
Material).
The results are expressed as mean± SD unless otherwise stated;
parametric data were analyzed with the Student’s t -test and
p< 0.05 was considered statistically significant. Statistical analysis
was performed using the SPSS software version 11.5.1 (2002, SPSS
base 11.0 for Windows SPSS Inc., Chicago, IL, USA).
RESULTS
In the AD group 63% of individuals were female and 37% male,
with an average age of 70.1± 8 years. The mean time of diagnosis
and follow-up in neurology consultation was of 16 months. These
patients were classified in clinical grounds as having AD in mod-
erate stage, with mini-mental state examination (MMSE) values
of 14.3± 6. In the N group, patients had the same population
characteristics but without any known neurodegenerative disease
(Table 1).
We found a statistically significant difference (p< 0.01)
between p-tau/KTP values in AD and N groups (Table 1). Regard-
ing p-tau in AD group the values were 403.2± 157.6 pg/mL
whereas in the N group the values were 68.8± 18.3 pg/mL
(p< 0.01). Regarding KTP in AD and N groups the values were
1.8± 0.62 and 3.4± 1.2 nM, respectively.
Figure 2A shows a plot of the p-tau and KTP concentrations
in the CSF of AD patients and control group (N). There is a clear
inverse correlation between the levels of p-tau and KTP in the
AD group (Pearson correlation coefficient of −0.69) in contrast
with the N group (Pearson correlation coefficient of −0.38), This
is corroborated by the application of a linear regression model
to fit the data: the slope is not significantly different from zero
in the N group (p= 0.22). The data was also clustered and the
average KTP level was plotted against the concentration of p-tau
for different classes (Figure 2B). This plot confirms that all data
points in N are in the lowest class of p-tau level while simul-
taneously having the highest average KTP level. All AD classes
have significantly lower levels of KTP than the control group,
N. In AD patients decreasing average KTP levels are concomi-
tant with increasing p-tau levels. The statistical analysis shows
that above 400 pg/mL all AD classes have significantly lower KTP
levels than the class 100–200 pg/mL. This result further supports
an inverse relationship between KTP and tau in the CSF of AD
patients.
DISCUSSION
Our study is in agreement with previous studies aiming at other
neuromolecules (Sulkava et al., 1985; Blennow et al., 2010) that
have shown that in AD and vascular dementia, as the disease
progresses several neuropeptides levels fall. Here we also found
a statistically significant difference in KTP levels between AD
patients and N individuals, being lower in the first. This can be
explained by to a disease-specific cortical thinning and hippocam-
pal volume loss, with an acceleration phase during the early stages
of the AD (Sabuncu et al., 2011), meaning less cortical mass, which
possibly results in less KTP production capability and KTP drop-
ping levels in the CSF of these patients (Figure 2). Moreover, there
Table 1 | Alzheimer’s disease patient characterization and CSF
concentration results (mean±SD; SE, standard error).
AD group N group p-Value
Male/female (%) 63/37 56/44 –
Age (years) 70±8 68±6 >0.01
KTP (nM) 1.8±0.6 (SE 0.1) 3.4±1.2 (SE 0.3) <0.01
p-Tau (pg/mL) 403.2±157.6 (SE 31.5) 68.8±18.3 (SE 5.2) <0.01
Frontiers in Aging Neuroscience www.frontiersin.org October 2013 | Volume 5 | Article 68 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Santos et al. Kyotorphin levels in Alzheimer’s disease
FIGURE 2 | p-Tau levels dependence on KTP concentration both in AD
(red) and N (white) group. (A) Complete data set with individual values. A
linear regression line (least squares method) is plotted as a guide to the
eye. (B) The data set presented in (A) was clustered in classes according to
regular intervals of amplitude of 100 pg/mL of p-tau concentration and
averaged for KTP concentration (all N group data are in the 1- to 100-pg/mL
p-tau interval and AD values are in classes above 100 pg/mL; error bars
represent standard error). The average KTP value of all classes was
compared to control (*p<0.04, **p< 0.0075, ***p<0.0006) or the 100-
to 200-pg/mL p-tau class (#p<00.04, ##p<0.0046) using the one-way
ANOVA with Dunnett’s post-test.
is an inverse correlation between p-tau and KTP in CSF in AD
patients. p-Tau in CSF acts as a marker of neurodegeneration,
being released from senescent neurons. KTP is also produced in
neuronal cells, its levels naturally falling as neurons die. As more
neuronal cells are destroyed in the course of the disease p-tau is
released and KTP production is impaired (Figure 2).
Lower levels of a molecule with analgesic properties such as
KTP may help to explain why AD patient population is believed
to have an increased incidence of hidden chronic pain (see Intro-
duction); in agreement, previous studies (Nishimura et al., 1991)
have shown that KTP levels decrease in chronic pain conditions.
Another potential implication of these results stems from the
FIGURE 3 | Outline of the potential clinical implications of the results
of the present study. Neuronal degeneration (increased p-tau levels) leads
to decreased KTP production and account to the detected decreased KTP
levels, which in turn causes a positive feedback loop potentiating neuronal
degeneration. Concomitantly, decreased KTP levels cause changes in
affective pain tolerance which may account to chronic pain installation. This
is particularly relevant as AD patients have limited capacity to report their
pain due to their cognitive impairments. Altogether, these conditions set
the severity of the clinical conditions of AD patients. Hope arises from the
potential use of KTP-related drugs with dual neuroprotective and analgesic
action, the latter being demonstrated for amidated kyotorphin (Ribeiro et al.,
2011a) and a tandem ibuprofen-KTP drug (Ribeiro et al., 2011b). In addition, a
decreased level of KTP in the CSF is a potential additional biomarker for AD.
correlation between KTP and NO production in AD patients as
lower levels of KTP might lead to a decreased NOS activity with
consequent fall of NO levels. This NO deficit and consequent
cerebral hypoperfusion (see Introduction) compromise further or
even help to initiate neurodegenerative deregulations characteris-
tic of AD, with increased both neuronal loss and levels of p-tau.
POTENTIAL IMPLICATIONS
One important implication of the results here presented is that
KTP is a candidate biomarker for neurodegeneration. Several
studies in animal models (Takagi et al., 1979; Nazarenko et al.,
1999; Santalova et al., 2004; Ribeiro et al., 2011b) have shown that
KTP functions not only as a potent endogenous analgesic mole-
cule but also as neuroprotector and neuromodulator. We suggest
further studies in animal models in order to unveil if exogenous
administration of KTP (with increase of its CSF levels) can result
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in neuroprotection. There is evidence of the KTP role in integra-
tive functions in animals, particularly in the field of exploratory
activity (Kolaeva et al., 2000), which are not inhibited by naloxone,
therefore independent of its analgesic effects. It is also important
to recall that amidated KTP and other KTP-related molecules have
important analgesic efficacy, as shown in previous studies (Ribeiro
et al., 2011a,b). A dual neuroprotective analgesic action in a single
drug would be of utmost importance.
In summary, this study points to KTP as a possible but over-
looked biomarker with potential clinical dual importance in the
context of pain and neurodegeneration in Alzheimer disease
(Figure 3).
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